Brazil Alexei Kolchin, general manager of GSK Brazil, discusses adapting to Brazil, having previously held the equivalent role in Russia, the Brazilian affiliate’s contribution to GSK’s global growth, and its embrace of digitally disruptive technologies. Before being appointed GM of GSK in Brazil, you were the GM for GSK Russia, so…
India A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB) in support of the Government of India’s efforts to end TB, including providing access to novel drug bedaquiline, initiating a…
India A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty generics has led them to success in both the Indian and US markets. When we met in 2011, the company…
Serbia Nenad Markovic, director of fast-growing, family-run pharmaceutical company ADOC in Serbia, sheds light on the organisation’s rapid and consistent growth, the ADOC stamp of approval and why the road to EU membership will be a smooth one for ADOC. What are ADOC’s current operations in Serbia? “We are very happy…
Lithuania Kristina Garuoliene, vice minister at the Ministry of Health of the Republic of Lithuania, explains the cornerstones behind the new National Drug Policy approved in August 2017, the commitment of the Ministry to ensuring Lithuanian patients have access to the latest high-quality medicines regardless of their location or spending power.…
Canada Dr. David Goodman, CEO of Pharmascience, talks about the strategy for the international expansion of the company, key for which are long-lasting partnerships. He also analyzes the re-organization of the company amongst the two main axes of generics and branded products and highlights its dedication to R&D, especially in the…
Poland Michał Mieszkowski, general manager of Angelini Poland, discusses the strategic significance of Poland for the company, as the third largest affiliate within the global company, the company’s impressive product portfolio and exciting pipeline, new therapeutic areas, and his future aspirations for Angelini Poland. As the general manager for Poland at…
Switzerland Dr. Teodoro Albarano, chief medical officer and vice CEO of Swiss skincare specialists Mavena, discusses why he decided to join the company after an illustrious career in Big Pharma, Mavena’s internationalization activities, and the importance of effective treatments for psoriasis. You decided to join Mavena a year ago after…
Serbia Claude Broudic, general manager for Servier in Serbia, highlights the potential for business in the country, Servier’s projects for expansion in the Balkans, and the skills needed to put together a good pharma team. What were your priorities when you took over as general manager of Servier Serbia? “When looking…
India Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized to reach sophisticated international markets. Mr. Mookim, could you give our international readers a brief introduction of IQVIA and explain…
Poland Stefan Buguslawski, president of PEX Pharmasequence, a leading Polish healthcare consultancy and market research company, highlights the current obstacles facing the Polish healthcare market and the dynamics of the domestic pharmaceutical industry. He also discusses the innovative services they provide and how their offering will develop in the future. As…
Brazil Fernando Silveira F°, country manager in Brazil of ISDIN, documents the successful market entry and rapid development of this dermatology focused company in Brazil, while ISDIN has managed to establish itself as the partner of choice of Brazilian dermatologists and patients and moreover holds exciting growth prospects moving forward. As…
See our Cookie Privacy Policy Here